{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:51:29Z","timestamp":1790862689708,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.neurol.2012.01.585","type":"journal-article","created":{"date-parts":[[2012,5,2]],"date-time":"2012-05-02T15:26:11Z","timestamp":1335972371000},"page":"927-938","source":"Crossref","is-referenced-by-count":6,"title":["What can we expect from the serotonergic side of l-DOPA?"],"prefix":"10.1016","volume":"168","author":[{"given":"P.","family":"De Deurwaerd\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Navailles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2012.01.585_bib0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0006-8993(90)91318-B","article-title":"Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats","volume":"525","author":"Abercrombie","year":"1990","journal-title":"Brain Res"},{"key":"10.1016\/j.neurol.2012.01.585_bib0010","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2012.01.585_bib0015","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1523\/JNEUROSCI.5196-09.2010","article-title":"VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety","volume":"30","author":"Amilhon","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0304-3940(95)11817-G","article-title":"l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study","volume":"195","author":"Arai","year":"1995","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurol.2012.01.585_bib0025","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2012.01.585_bib0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","article-title":"Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study","volume":"253","author":"Barone","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0035","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0040","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1353-8020(09)70827-2","article-title":"Dopamine receptors and l-DOPA-induced dyskinesia","volume":"15 Suppl. 4","author":"Berthet","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2012.01.585_bib0045","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1051\/medsci\/20102610800","article-title":"GRK6, a new therapeutic approach to alleviate l-DOPA-induced dyskinesia","volume":"26","author":"Berthet","year":"2010","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.neurol.2012.01.585_bib0050","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","article-title":"Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models","volume":"57","author":"Bibbiani","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2012.01.585_bib0055","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0149-7634(96)00032-2","article-title":"Dopamine and glutamate control each other's release in the basal ganglia: a microdialysis study of the entopeduncular nucleus and substantia nigra","volume":"21","author":"Biggs","year":"1997","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.neurol.2012.01.585_bib0060","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/jnr.21978","article-title":"Contribution of the striatum to the effects of 5-HT1A receptor stimulation in l-DOPA-treated hemiparkinsonian rats","volume":"87","author":"Bishop","year":"2009","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.neurol.2012.01.585_bib0065","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1111\/j.1460-9568.2006.04790.x","article-title":"MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation","volume":"23","author":"Bishop","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0075","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0035-3787(04)71067-X","article-title":"Central dopamine receptors: general considerations (Part 1)","volume":"160","author":"Bordet","year":"2004","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2012.01.585_bib0080","doi-asserted-by":"crossref","first-page":"III\/1","DOI":"10.1007\/s00415-002-1301-4","article-title":"Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)","volume":"249 Suppl. 3","author":"Braak","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0085","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1523\/JNEUROSCI.0015-10.2010","article-title":"Coding of task reward value in the dorsal raphe nucleus","volume":"30","author":"Bromberg-Martin","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0090","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.neuron.2010.11.022","article-title":"Dopamine in motivational control: rewarding, aversive, and alerting","volume":"68","author":"Bromberg-Martin","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neurol.2012.01.585_bib0095","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1212\/WNL.53.6.1212","article-title":"FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa","volume":"53","author":"Brown","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2012.01.585_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/newbio245123a0","article-title":"Comparison of effects of l-DOPA, amphetamine and apomorphine on firing rate of rat dopaminergic neurones","volume":"245","author":"Bunney","year":"1973","journal-title":"Nat New Biol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0105","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1523\/JNEUROSCI.20-22-08443.2000","article-title":"Dopamine and cAMP-regulated phosphoprotein 32kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity","volume":"20","author":"Calabresi","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0110","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0166-2236(90)90108-M","article-title":"Interactions between glutamatergic and monoaminergic systems within the basal ganglia\u00a0\u2013\u00a0implications for schizophrenia and Parkinson's disease","volume":"13","author":"Carlsson","year":"1990","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0115","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2012.01.585_bib0120","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/mds.22792","article-title":"Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease","volume":"25 Suppl. 1","author":"Carta","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2012.01.585_bib0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00726-001-0116-4","article-title":"Transcription factors involved in the pathogenesis of l-DOPA-induced dyskinesia in a rat model of Parkinson's disease","volume":"23","author":"Cenci","year":"2002","journal-title":"Amino Acids"},{"key":"10.1016\/j.neurol.2012.01.585_bib0130","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1353-8020(09)70828-4","article-title":"Rodent models of treatment-induced motor complications in Parkinson's disease","volume":"15 Suppl. 4","author":"Cenci","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2012.01.585_bib0135","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.50.5_Suppl_5.S17","article-title":"Levodopa therapy: consequences of the non-physiologic replacement of dopamine","volume":"50","author":"Chase","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2012.01.585_bib0140","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM196803142781127","article-title":"l-DOPA for Parkinsonism","volume":"278","author":"Cotzias","year":"1968","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2012.01.585_bib0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of Parkinsonism\u00a0\u2013\u00a0chronic treatment with l-DOPA","volume":"280","author":"Cotzias","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2012.01.585_bib0150","series-title":"La s\u00e9rotonine","article-title":"Aspects physiologiques et physiopathologiques de la transmission s\u00e9rotoninergique au sein des ganglions de la base","author":"De Deurwaerd\u00e8re","year":"2011"},{"key":"10.1016\/j.neurol.2012.01.585_bib0155","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias","volume":"127","author":"de la Fuente-Fernandez","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2012.01.585_bib0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fnsys.2011.00031","article-title":"Noradrenaline and Parkinson's disease","volume":"5","author":"Delaville","year":"2011","journal-title":"Front Syst Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0560","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.nbd.2011.10.023","article-title":"Emerging dysfunctions consequent to multiple monoaminergic depletions in experimental parkinsonism","volume":"45","author":"Delaville","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurol.2012.01.585_bib0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0079-6123(08)00921-7","article-title":"Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders","volume":"172","author":"Di Matteo","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.neurol.2012.01.585_bib0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainres.2007.05.005","article-title":"The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat","volume":"1158","author":"Dupre","year":"2007","journal-title":"Brain Res"},{"key":"10.1016\/j.neurol.2012.01.585_bib0180","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1212\/WNL.45.10.1855","article-title":"Levodopa-induced dyskinesias are improved by fluoxetine","volume":"45","author":"Durif","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2012.01.585_bib0185","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gps.1456","article-title":"Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease","volume":"21","author":"Ehrt","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.neurol.2012.01.585_bib0190","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.neubiorev.2010.06.007","article-title":"Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment","volume":"35","author":"Eskow Jaunarajs","year":"2011","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.neurol.2012.01.585_bib0195","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of l-DOPA-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.neurol.2012.01.585_bib0200","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0022-510X(71)90178-X","article-title":"Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor","volume":"14","author":"Fahn","year":"1971","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0205","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.22473","article-title":"Serotonin and Parkinson's disease: on movement, mood, and madness","volume":"24","author":"Fox","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2012.01.585_bib0210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2012.01.585_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-510X(73)90050-6","article-title":"Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa","volume":"19","author":"Gumpert","year":"1973","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0220","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1523\/JNEUROSCI.15-09-06157.1995","article-title":"Activation of dopamine cell firing by repeated l-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to l-DOPA treatment","volume":"15","author":"Harden","year":"1995","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0022-3565(25)32511-5","article-title":"The site of dopamine formation in rat striatum after l-DOPA administration","volume":"217","author":"Hefti","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2012.01.585_bib0230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-3565(25)31520-X","article-title":"Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity","volume":"208","author":"Hollister","year":"1979","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2012.01.585_bib0235","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0031-6997(25)07154-6","article-title":"Dopamine (3-hydroxytyramine) and brain function","volume":"18","author":"Hornykiewicz","year":"1966","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.neurol.2012.01.585_bib0240","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/oxfordjournals.bmb.a070990","article-title":"Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of l-DOPA)","volume":"29","author":"Hornykiewicz","year":"1973","journal-title":"Br Med Bull"},{"key":"10.1016\/j.neurol.2012.01.585_bib0245","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1523\/JNEUROSCI.23-27-09107.2003","article-title":"3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates","volume":"23","author":"Iravani","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0250","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\\ increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2012.01.585_bib0255","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF03159935","article-title":"Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway","volume":"14","author":"Jellinger","year":"1991","journal-title":"Mol Chem Neuropathol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0260","doi-asserted-by":"crossref","first-page":"277S","DOI":"10.1111\/j.1365-2125.1983.tb05876.x","article-title":"Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease","volume":"15 Suppl. 2","author":"Jenner","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0265","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1471-4159.2000.0740263.x","article-title":"Reserpine pretreatment prevents increases in extracellular striatal dopamine following l-DOPA administration in rats with nigrostriatal denervation","volume":"74","author":"Kannari","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurol.2012.01.585_bib0270","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1046\/j.1471-4159.2001.00184.x","article-title":"Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation","volume":"76","author":"Kannari","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurol.2012.01.585_bib0275","first-page":"120","article-title":"Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease","volume":"131","author":"Kish","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2012.01.585_bib0280","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1523\/JNEUROSCI.4080-10.2011","article-title":"A genetically defined morphologically and functionally unique subset of 5-HT neurons in the mouse raphe nuclei","volume":"31","author":"Kiyasova","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0285","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000114631","article-title":"Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for l-DOPA therapy","volume":"12","author":"Korf","year":"1974","journal-title":"Eur Neurol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0290","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00213-007-1030-6","article-title":"The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram","volume":"197","author":"Kuan","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neurol.2012.01.585_bib0295","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurol.2012.01.585_bib0300","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1126\/science.170.3963.1212","article-title":"Parkinson's disease: activity of l-DOPA decarboxylase in discrete brain regions","volume":"170","author":"Lloyd","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.neurol.2012.01.585_bib0305","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0306-4522(00)00588-1","article-title":"Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum","volume":"103","author":"Lopez","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurol.2012.01.585_bib0310","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0006-8993(98)01248-7","article-title":"Loss of regulation by presynaptic dopamine D2 receptors of exogenous l-DOPA-derived dopamine release in the dopaminergic denervated striatum","volume":"817","author":"Maeda","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.neurol.2012.01.585_bib0315","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1007\/s11064-007-9351-8","article-title":"Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway","volume":"32","author":"Mandel","year":"2007","journal-title":"Neurochem Res"},{"key":"10.1016\/j.neurol.2012.01.585_bib0320","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-008-1452-9","article-title":"Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats","volume":"204","author":"Marin","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neurol.2012.01.585_bib0325","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1523\/JNEUROSCI.4346-06.2007","article-title":"The nociceptin\/orphanin FQ receptor antagonist J-113397 and l-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway","volume":"27","author":"Marti","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0330","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.nbd.2006.01.009","article-title":"Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine","volume":"22","author":"Meissner","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurol.2012.01.585_bib0335","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/283772a0","article-title":"Serotonergic neurones are not involved in action of l-DOPA in Parkinson's disease","volume":"283","author":"Melamed","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.neurol.2012.01.585_bib0340","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1476-5381.1990.tb15792.x","article-title":"Responses of rat substantia nigra compacta neurones to l-DOPA","volume":"100","author":"Mercuri","year":"1990","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0345","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1046\/j.1471-4159.1999.721516.x","article-title":"Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous l-DOPA: studies in intact and 6-hydroxydopamine-treated rats","volume":"72","author":"Miller","year":"1999","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurol.2012.01.585_bib0350","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1097\/00004714-198712001-00002","article-title":"Serotonergic neuronal systems: what their anatomic organization tells us about function","volume":"7","author":"Molliver","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0355","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia","volume":"131","author":"Munoz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2012.01.585_bib0360","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/096368970000900502","article-title":"The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models","volume":"9","author":"Nakamura","year":"2000","journal-title":"Cell Transplant"},{"key":"10.1016\/j.neurol.2012.01.585_bib0365","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1523\/JNEUROSCI.0021-08.2008","article-title":"Reward-dependent modulation of neuronal activity in the primate dorsal raphe nucleus","volume":"28","author":"Nakamura","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0370","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1523\/JNEUROSCI.5031-09.2010","article-title":"High-frequency stimulation of the subthalamic nucleus and l-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease","volume":"30","author":"Navailles","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0375","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","article-title":"Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease","volume":"38","author":"Navailles","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurol.2012.01.585_bib0380","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.nbd.2010.11.007","article-title":"Chronic l-DOPA therapy alters central serotonergic function and l-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease","volume":"41","author":"Navailles","year":"2011","journal-title":"Neurobiol Dis"},{"issue":"2\u20133","key":"10.1016\/j.neurol.2012.01.585_bib0385","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00213-010-2029-y","article-title":"Presynaptic control of serotonin on striatal dopamine function","volume":"213","author":"Navailles","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neurol.2012.01.585_bib0565","first-page":"323686","article-title":"Imbalanced dopaminergic transmission mediated by serotonergic neurons in l-DOPA-induced dyskinesia","volume":"2012","author":"Navailles","year":"2012","journal-title":"Parkinson's Dis"},{"key":"10.1016\/j.neurol.2012.01.585_bib0395","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mds.22760","article-title":"Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study","volume":"25","author":"N\u00e8gre-Pag\u00e8s","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2012.01.585_bib0400","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.170.3953.76","article-title":"l-DOPA-induced release of cerebral monoamines","volume":"170","author":"Ng","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.neurol.2012.01.585_bib0405","first-page":"S30","article-title":"The basal ganglia in Parkinson's disease: current concepts and unexplained observations","volume":"64 Suppl. 2","author":"Obeso","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0410","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","article-title":"Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)","volume":"27","author":"Olanow","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0415","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/0014-4886(92)90203-3","article-title":"Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the \u201chemiparkinsonian\u201d rat","volume":"115","author":"Orosz","year":"1992","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0420","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.neuropharm.2011.05.021","article-title":"Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation","volume":"61","author":"Ostock","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurol.2012.01.585_bib0425","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.neuro.2005.02.002","article-title":"Pathological synaptic plasticity in the striatum: implications for Parkinson's disease","volume":"26","author":"Picconi","year":"2005","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neurol.2012.01.585_bib0430","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.nbd.2010.05.028","article-title":"Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study","volume":"40","author":"Politis","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurol.2012.01.585_bib0435","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2012.01.585_bib0440","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1523\/JNEUROSCI.09-09-03326.1989","article-title":"Evidence that l-DOPA-induced rotational behavior is dependent on both striatal and nigral mechanisms","volume":"9","author":"Robertson","year":"1989","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0445","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0450","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00173540","article-title":"Biotransformation of l-DOPA in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study","volume":"346","author":"Sarre","year":"1992","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0455","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/BF01294722","article-title":"Biotransformation of locally applied precursors of dopamine, serotonin and noradrenaline in striatum and hippocampus: a microdialysis study","volume":"104","author":"Sarre","year":"1997","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurol.2012.01.585_bib0460","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00702-005-0368-3","article-title":"Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data","volume":"113","author":"Scholtissen","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurol.2012.01.585_bib0465","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1212\/WNL.58.10.1501","article-title":"Increased risk of Parkinson's disease after depression: a retrospective cohort study","volume":"58","author":"Schuurman","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2012.01.585_bib0470","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0031-6997(25)06839-5","article-title":"Brain dopamine receptors","volume":"32","author":"Seeman","year":"1980","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.neurol.2012.01.585_bib0475","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/1531-8257(200007)15:4<669::AID-MDS1011>3.0.CO;2-5","article-title":"Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study","volume":"15","author":"Shiba","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2012.01.585_bib0480","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1111\/j.1460-9568.2006.04758.x","article-title":"l-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus","volume":"23","author":"Soghomonian","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neurol.2012.01.585_bib0485","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1212\/WNL.34.12.1609","article-title":"Pharmacologic effects of l-DOPA are not closely linked temporally to striatal dopamine concentration","volume":"34","author":"Spencer","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2012.01.585_bib0490","unstructured":"Steinbusch HW. Serotonin-immunoreactive neurons and their projections in the CNS. In: Bj\u00f6rklund AHT, Kuhar MJ, editors. Handbook of Chemical Neuroanatomy\u00a0\u2013\u00a0Classical transmitters and transmitters receptors in the CNS Part II. Amsterdam: Elsevier; 1984. p.\u00a068\u2013125."},{"key":"10.1016\/j.neurol.2012.01.585_bib0495","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuropharm.2011.01.006","article-title":"Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus?","volume":"61","author":"Tan","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurol.2012.01.585_bib0500","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","article-title":"Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats","volume":"10","author":"Tanaka","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.neurol.2012.01.585_bib0505","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/archneur.1996.00550020087019","article-title":"The occurrence of depression in Parkinson's disease. A community-based study","volume":"53","author":"Tandberg","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0510","doi-asserted-by":"crossref","first-page":"17087","DOI":"10.1073\/pnas.0704144104","article-title":"Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus","volume":"104","author":"Temel","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2012.01.585_bib0515","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02251134","article-title":"The metabolism of exogenous l-DOPA in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain","volume":"3","author":"Tison","year":"1991","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.neurol.2012.01.585_bib0520","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0361-9230(94)90092-2","article-title":"Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats","volume":"35","author":"Tucci","year":"1994","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.neurol.2012.01.585_bib0525","doi-asserted-by":"crossref","first-page":"13159","DOI":"10.1073\/pnas.1003432107","article-title":"Presynaptic dopaminergic compartment determines the susceptibility to l-DOPA-induced dyskinesia in rats","volume":"107","author":"Ulusoy","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2012.01.585_bib0530","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(09)70287-X","article-title":"Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders","volume":"8","author":"Voon","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0535","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pneurobio.2010.06.008","article-title":"a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity","volume":"92","author":"Weinreb","year":"2010","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.neurol.2012.01.585_bib0540","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/mds.20555","article-title":"Antidepressant studies in Parkinson's disease: a review and meta-analysis","volume":"20","author":"Weintraub","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2012.01.585_bib0545","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/00001756-200105080-00015","article-title":"Fluoxetine reduces l-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum","volume":"12","author":"Yamato","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.neurol.2012.01.585_bib0550","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.nbd.2010.08.004","article-title":"Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia","volume":"40","author":"Zeng","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurol.2012.01.585_bib0555","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0166-2236(90)90112-N","article-title":"Compensations after lesions of central dopaminergic neurons: some clinical and basic implications","volume":"13","author":"Zigmond","year":"1990","journal-title":"Trends Neurosci"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378712007278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378712007278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T01:21:16Z","timestamp":1743038476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378712007278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":111,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0035378712007278"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2012.01.585","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}